Blog Post

ReAlta’s CEO Dr. Ulrich Thienel will be attending the BIO International Convention on Monday, June 5^th through Thursday, June 8^th in Boston.  Dr. Thienel will be meeting with investors and potential business partners to discuss the latest developments in our EPICC technology platform, including the upcoming Phase 2 clinical trial for our lead compound, RLS-0071, in hypoxic-ischemic encephalopathy (HIE).  Dr. Thienel will also share highlights from the presentation of exciting new data from the recently completed Phase 1b proof of mechanism study at this week’s American Thoracic Society 2023 annual meeting.